Ronan Abgral

Brest, 29200, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 118 publications

Complementary Findings of 18F-FDG and 68Ga-FAPI-46 PET/CT in a Chronic Left Ventricular Aneurysm.

Complementary Findings of 18F-FDG and 68Ga-FAPI-46 PET/CT in a Chronic Left Ventricular Aneurysm.

Journal: Clinical nuclear medicine
Published: March 23, 2026

A Rare Case of Four-year Complete Metabolic Response in Multisystem Anti-Jo-1 Antisynthetase Syndrome Assessed by 18 F-FDG PET/CT.

A Rare Case of Four-year Complete Metabolic Response in Multisystem Anti-Jo-1 Antisynthetase Syndrome Assessed by 18 F-FDG PET/CT.

Journal: Clinical nuclear medicine
Published: March 06, 2026

Diagnostic accuracy of 18F-FDG PET-CT scores in distinguishing polymyalgia rheumatica from other inflammatory rheumatic diseases: a multicentre retrospective study (RHUMATEP).

Diagnostic accuracy of 18F-FDG PET-CT scores in distinguishing polymyalgia rheumatica from other inflammatory rheumatic diseases: a multicentre retrospective study (RHUMATEP).

Journal: European journal of nuclear medicine and molecular imaging
Published: March 02, 2026

Case Report: long complete metabolic response assessed by LAFOV FDG-PET/CT to FOLFIRINOX in first-line treatment of metastatic low-differentiated pancreatic carcinoma.

Case Report: long complete metabolic response assessed by LAFOV FDG-PET/CT to FOLFIRINOX in first-line treatment of metastatic low-differentiated pancreatic carcinoma.

Journal: Frontiers in medicine
Published: January 15, 2026

PRognostic and predictive potential Of multiparametric dynamic whole-body 18F-FDG PET Imaging using a Long axial field-of-view (LAFOV) system for FIRST-line chemo-immunotherapy efficacy in advanced non-small cell lung cancer: PROFIL-1 study protocol.

PRognostic and predictive potential Of multiparametric dynamic whole-body 18F-FDG PET Imaging using a Long axial field-of-view (LAFOV) system for FIRST-line chemo-immunotherapy efficacy in advanced non-small cell lung cancer: PROFIL-1 study protocol.

Journal: PloS one
Published: November 11, 2025

Development and external validation of a FDG PET-based radiomics model predicting occult lymph node metastasis in non-small cell lung cancer patients.

Development and external validation of a FDG PET-based radiomics model predicting occult lymph node metastasis in non-small cell lung cancer patients.

Journal: European journal of nuclear medicine and molecular imaging
Published: November 03, 2025

Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group.

Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: September 05, 2025

The Importance of PET Quantification for Prognosis and Treatment Response Monitoring.

The Importance of PET Quantification for Prognosis and Treatment Response Monitoring.

Journal: PET clinics
Published: August 26, 2025

Prognostic value of TMTV and Dmax calculated from 18F-fluorodeoxyglucose positron emission tomography images in metastatic cutaneous melanoma treated with immune checkpoint blockade.

Prognostic value of TMTV and Dmax calculated from 18F-fluorodeoxyglucose positron emission tomography images in metastatic cutaneous melanoma treated with immune checkpoint blockade.

Journal: European journal of nuclear medicine and molecular imaging
Published: July 30, 2025

18F-FDG PET radiomic analysis to predict outcomes in metastatic melanoma treated with immune checkpoint inhibitors.

18F-FDG PET radiomic analysis to predict outcomes in metastatic melanoma treated with immune checkpoint inhibitors.

Journal: Frontiers in immunology
Published: June 06, 2025

Survival impact of a KEAP1-NFE2L2 radiomics model in PDL1 ≥ 50% non-small cell lung cancer treated with pembrolizumab: the PEMBROMIC study.

Survival impact of a KEAP1-NFE2L2 radiomics model in PDL1 ≥ 50% non-small cell lung cancer treated with pembrolizumab: the PEMBROMIC study.

Journal: Cancer imaging : the official publication of the International Cancer Imaging Society
Published: March 08, 2025

MHC class II: a predictor of outcome in melanoma treated with immune checkpoint inhibitors.

MHC class II: a predictor of outcome in melanoma treated with immune checkpoint inhibitors.

Journal: Melanoma research
Published: February 13, 2025
Showing 1-12 of 118

Last Updated: 09/26/2026